Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy al...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco Donia, Rikke Andersen, Troels Holz Borch, Özcan Met, Eva Ellebaek, Inge Marie Svane
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000668.full
Tags: Add Tag
No Tags, Be the first to tag this record!